Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Terbinafine shows dose-dependency in tinea capitis
New Orleans - Dose rather than duration of therapy appears to be the important factor for achieving favorable cure rates using oral terbinafine (Lamisil) for the treatment of tinea capitis, Sheila Fallon Friedlander, M.D., said at the annual meeting of the American Academy of Dermatology.
Related Videos
Related Content
